TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: General adolescent health knowledge assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete response (CR) in delay phase of CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightly duration of Non-Invasive Ventilation use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S3-NIV (Non-Invasive Ventilation) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of hospitalizations during the study period
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Weighted Pediatric Readiness Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of associated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life/recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biodistribution of 64Cu-LNTH-1363S
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal dose (radioactivity and mass dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of biodistribution with Immunohistochemistry FAP expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Disorder Examination Interview (EDE) Global Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change during active treatment on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change during follow-up on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change during active treatment on the PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change during follow-up on the PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator Global Assessment (IGA) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Body Surface Area (BSA) affected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCS uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of low blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restoration of hand mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nutrition knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of respiratory distress due to upper airway obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in oxytocin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive Impairment (MMSE <24 points or diagnosis of Neurocognitive disorder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: wound recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ADL scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in QMG scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasopharyngeal carriage rate of Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of flares experienced by a patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Body Image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dysfunctional Eating Behaviours and Risk of Developing Eating Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to break in remote monitoring
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of LF-MRI in stroke diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: General fatigue scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Difference in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of PrEP and MOUD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Sensory Organization Test (SOT) Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dizziness Handicap Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Activities-specific Balance Confidence Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major Amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sit & Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of 89Zr-panitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 89Zr-panitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pacemaker Atrial (P Wave) Over-Sensed Events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of the Emergency Call
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Readability of Nutrition Messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thematic Relevance of Nutrition Messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical Relevance to Colorectal Cancer Survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Effectiveness of Nutrition Messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Potential for Implementation in Clinical Practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Experiencing a Serious or Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of healthcare workers involved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adolescent/Adult Sensory Profile (AASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Perception Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Motor Competence Questionnaire (AMCQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycosylated hemoglobin in diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Reaching Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSCL-25 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended phase 2 dose (RP2D) of SC-43
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preliminary antitumor activity of SC-43
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with ventricular tachycardia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: diaphragm stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profile of Mood States (POMS) - Anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Perceived stress level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of continuous glucose monitor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower Respiratory Tract Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes of the intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: changes of the visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: changes of the central corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Outcome of children with Thrombocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Usability using the System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality using the Mobile Application Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Engagement with the Portfolio Diet App
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in fasting serum lipoprotein and cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting and postprandial plasma triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting and postprandial plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceleration and maintenance of a faster sinus rhythm after PVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of AV conduction efficiency and its durability after PVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of AF during the observation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of women agreeing to outreach educational program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pterygium hyperemia grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Total Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Nutritional Deficiency in Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Nutritional Deficiency in Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Nutritional Deficiency in Iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Goniometric measurement of Neck Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Microbiota Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with changed treatment plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Venous Excess Ultrasound Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling about teleworking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stigma score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: discharge mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in central macular thickness (CMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: local field potential power (amplitude)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: local field potential frequency (Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of screening questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of air artefacts during positive pressure ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abilhand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEC-Lobo
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Function in Sitting Test (FIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of heart failure within 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Patient Activation Measure Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gross Motor Function Measure scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Catheter Dwell Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Crestal bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of cerebrospinal fluid (CSF) Cryptococcus clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ataxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in walking capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Self-Awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Breast Milk Supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prognosis of pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Prognosis of mechanically ventilated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post treatment histopathologic resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of arrhythmia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of MK-1084
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of MK-1084
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of MK-1084
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-related clinical features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nasal volume, minimum cross-sectional area, and total nasal resistance at 75Pa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative serum cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in spherical equivalent error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematical measurement of shoulder abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30-day successful rate after device implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first request of rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoalbuminemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion rate of Cereset intervention by ortho trauma unit staff
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Learning Task Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Monitoring of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of infusion related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Monitoring of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring of clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in equivalent spherical lens value after cycloplegia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma concentration [Cmax] of Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma concentration [Tmax] of Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Ketamine HCl PR oral tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal behavioural assessment scale (NBAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-born Behavioral Observations (NBO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative Assessment of General Movements (GMsA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karitane Parenting Confidence scale (KPCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Stress Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sexological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk flexion endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prone bridge test (plank) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sorensen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of vasoactive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective effects of nicotine nasal spray as measured by the Nicotine Effects Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective effects of nicotine nasal spray as measured by a visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reinforcing effects of nicotine nasal spray
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Whole-Body Sweat Losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resolution of tearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of fluorescein dye disappearance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of virtual agent vs. human agent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postinjection sacroiliac pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postinjection disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cost effectiveness as measured by costs per patient screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost effectiveness as measured by cost per case found
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: grade 3-4 adverse events related to amikacin
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of Proposed Screening Method
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Proposed Screening Method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status